Acelyrin

2024 was a challenging year for the biopharma industry, with companies like Bayer, Bristol Myers Squibb, and Johnson & Johnson cutting hundreds to thousands of jobs. Cassava Sciences announced layoffs of 10 employees, 33% of its workforce, following a failed Phase III trial for its Alzheimer's drug. CytomX Therapeutics cut 40% of its staff to focus on clinical programs. Velia, a San Diego biotech, is shutting down, affecting 47 employees. Regeneron's acquisition of Oxular led to layoffs, with no Oxular employees joining Regeneron. Javara, Ring Therapeutics, Outlook Therapeutics, Editas, Bavarian Nordic, BenevolentAI, Chroma Medicine and Nvelop Therapeutics, Cellectar Biosciences, Carisma Therapeutics, Belharra Therapeutics, National Resilience, AmplifyBio, Agenus, Alligator Bioscience, Idorsia Pharmaceuticals, Kronos Bio, Novartis, Recursion Therapeutics, Medigene, Alector, Bristol Myers Squibb, Sonata Therapeutics, 23andMe, Johnson & Johnson, Merck, Gilead Sciences, Adaptimmune, Sensei Biotherapeutics, Marinus Pharmaceuticals, Orna Therapeutics, Thermo Fisher Scientific, Charles River Laboratories, Aurinia Pharmaceuticals, Viracta Therapeutics, Astellas Gene Therapies, Sana Biotechnology, Sage Therapeutics, Compass Pathways, Spero Therapeutics, ICON, Pfizer, Takeda, SalioGen Therapeutics, Evonik, Medtronic, CareFusion Resources, Turnstone Biologics, Leo Pharma, Astellas Pharma, Prime Medicine, Kaléo, Stryker, Relay Therapeutics, ImmunityBio, Shattuck Labs, Inventprise, bluebird bio, Athira Pharma, AGC Biologics, Oncternal Therapeutics, Biosense Webster, Vesigen Therapeutics, Connect Biopharma, BioMarin, IN8bio, Edwards Lifesciences, DermTech, Repare Therapeutics, Genentech, Tome Biosciences, Aadi Bioscience, Lykos Therapeutics, Evotec, Galera Therapeutics, Grail, Ovid Therapeutics, Lexicon Pharmaceuticals, Acelyrin, Boundless Bio, FibroGen, Ajinomoto Bio-Pharma Services, AN2 Therapeutics, Entero Therapeutics, Precigen, Sumitomo Pharma America, uniQure, Vir Biotechnology, Arbutus Biopharma, HilleVax, and Bayer also announced significant layoffs, reflecting a tough year for the industry.

Acelyrin shifted focus to lonigutamab after discontinuing izokibep investments, despite positive Phase III HS data, leading to a 33% workforce cut. Izokibep was dropped following a failed Phase IIb/III uveitis study. Acelyrin's stock fell despite positive Phase II thyroid eye disease data.

Acelyrin's Phase II trial for lonigutamab in thyroid eye disease showed symptom improvements but led to a 36% stock drop. The drug may be safer than Tepezza, with Phase III trials planned. Lonigutamab, a potential Tepezza competitor, could generate $624m by 2030 if approved.

Acelyrin advances lonigutamab to Phase III for thyroid eye disease, facing competition from Tepezza and Viridian's Phase III candidate.

Derek Archila of Wells Fargo maintains a Buy rating on ACELYRIN, INC. (SLRN) with a $13.00 price target, citing promising Phase 1/2 trial results for Lonigutamab. The drug shows potential safety advantages and efficacy comparable to competitors, supporting its advancement to Phase 3 trials. Piper Sandler also reiterates a Buy rating with a $20.00 target.

ACELYRIN, INC. announced Phase 2 data for lonigutamab in Thyroid Eye Disease (TED), showing efficacy and safety. A Phase 3 program, LONGITUDE, is set to start in Q1 2025, with topline data expected in late 2026. Lonigutamab offers a potential safer, effective, and convenient TED treatment alternative.

Lonigutamab shows promise for Thyroid Eye Disease (TED) with efficacy comparable to standard care and a favorable safety profile. Phase 3 trials, LONGITUDE-1 and LONGITUDE-2, are set to begin in Q1 2025, with topline data expected in late 2026. The trials aim to evaluate lonigutamab's safety and efficacy in ~350 patients globally.

Acelyrin advances lonigutamab to Phase III for thyroid eye disease, facing competition from Tepezza and Viridian's Phase III candidate.

SLRN stock hit a 52-week low at $2.2, showing a -53.71% yearly decline but an 11.15% weekly gain, suggesting undervaluation. Despite market volatility, SLRN maintains strong liquidity and financial stability. Acelyrin Inc. adjusted its Phase 3 program for lonigutamab, with trials starting Q1 2025. Analysts have mixed ratings, with some highlighting positive trial data and pipeline progress.

ACELYRIN, INC. advances lonigutamab into Phase 3 trials for Thyroid Eye Disease (TED) after promising Phase 2 results. The drug, a monoclonal antibody targeting IGF-1 receptor, shows efficacy and safety. Phase 3 trials, LONGITUDE-1 and LONGITUDE-2, will involve 350 patients globally, assessing safety and efficacy. ACELYRIN's financials are strong, with a cash runway extending through mid-2027.